Introduction
p53 is a major constituent of cellular damage control pathways (Lane, 1992; Smith et al., 1995; Kinzler and Vogelstein, 1996) . p53 responses, at the level of accumulation and transcriptional activation are recorded as cellular responses to DNA damage caused by a variety of agents such as ionizing and U.V.-radiation, alkylating agents and DNA nucleases (Maltzman and Czyzyk, 1984; Kastan et al., 1991 Kastan et al., , 1992 Lu and Lane, 1993; Zhan et al., 1993; Nelson and Kastan, 1994) . Activation of p53 leads to cell growth arrest in G 1 or G 2 phases of the cell cycle, thus presumably giving cells time to repair their damaged DNA thereby preventing the accumulation of genetically damaged cells (Kastan et al., 1991; Kuerbitz et al., 1992; Dulic' et al., 1994) . Alternatively, p53 has been implied to route the cells to an apoptotic pathway thus discarding cells with potentially harmful genetic lesions (Clarke et al., 1993; Lowe et al., 1993) . The function of p53 involves its ability to bind DNA sequence-speci®cally (Kern et al., 1991; El-Deiry et al., 1992; Farmer et al., 1992) , although the transcriptional activity of p53 is not always needed for the apoptotic response (Caelles et al., 1994; Wagner et al., 1994) . However, the importance of an intact DNA-binding activity to p53 function is stressed by the high frequency of mutations in the speci®c DNA-binding domain in human cancers (Hollstein et al., 1994) . p53 transactivates promoters containing a p53-responsive element but suppresses other target promoters possibly by interacting with the TATA-binding protein (Ginsberg et al., 1991; Seto et al., 1992; Liu et al., 1993; Mack et al., 1993) . p53 responsive genes include potential regulators of cell growth, DNA repair and apoptosis, such as p21 CIP-1/WAF-1 (El-Deiry et al., 1993) , GADD45 , bax-1 (Miyashita and Reed, 1995) , cyclin G (Okamoto and Beach, 1994) and mdm-2 (Barak et al., 1993; Wu et al., 1993) . The role of p21 CIP-1/WAF-1 as a mediator of p53 eects has been of particular interest because of its ability to interact with central components of the cell cycle machinery (Harper et al., 1993) . Furthermore, the ability of p53 to bind DNA lesions and DNA strand ends (Oberosler et al., 1993; Bakalkin et al., 1994; Lee et al., 1995) is concordant with its function in cellular damage repair.
Wild type p53 binds to its consensus DNA site as a tetramer (Friedman et al., 1993) , although some wildtype-like activities are retained by monomeric p53 proteins (Slingerland et al., 1993; Tarunina and Jenkins, 1993; Marston et al., 1995) . In normal cells p53 has a short half with less than 30 min (Maltzman and Czyzyk, 1984; Reich and Levine, 1984) and is in an apparently latent state. The speci®c DNA-binding capacity of p53 requires its tetramerization and conformational activation. Upon activation, the central DNA-binding domain of p53 tetramer is exposed facilitating DNA-binding, whereas in the latent form the DNA-binding activity is masked possibly by the Cterminal basic region (Hupp et al., 1992 Hupp and Lane, 1994b) . In support of C-terminal modifications required for p53 conformational changes 20-mer peptides derived from the C-terminal region eectively compete with the regulatory domain for binding to the core of p53 molecule, thus inducing a conformational change with exposed sequence-speci®c DNA-binding domain . Similarly, the binding of a monoclonal antibody (PAb 421) directed against the Cterminal domain of p53 and deletion of the C-terminal part of the molecule mimic post-transcriptional modi®cations and activate the DNA-binding ability (Hupp et al., 1992; . Mechanisms and eectors that induce a conformational change in p53 are subject of intense investigation. Posttranslational modi®cations, especially p53 phosphorylation appears to be involved in the activation process. p53 is phosphorylated in vitro by a number of kinases, including p34 cdc2 (Addison et al., 1990; Bischo et al., 1990) , double-stranded DNA-activated protein kinase (Lees-Miller et al., 1990; Wang and Eckhart, 1992) , casein kinase I , casein kinase II (Meek et al., 1990; Herrmann et al., 1991; , MAP kinase (Milne et al., 1994) , protein kinase C (PKC) (Baudier et al., 1992; Takenaka et al., 1995; Milne et al., 1996) , raf-1 (Jamal and Zi, 1995) and JNK1 (Milne et al., 1995) . Some of these phosphorylation events, especially those involving the C-terminal domain of p53 regulate the DNAbinding activity of p53 in vitro when puri®ed components are used. The phosphorylation of amino acids 370 and 377 by PKC has been shown to activate the latent sequence-speci®c DNA-binding activity of p53 and lead to loss of reactivity to monoclonal antibody PAb 421 (Delphin and Baudier, 1994; Hupp and Lane, 1994a; Takenaka et al., 1995) . The relevance of phosphorylation events and role of dierent kinases in vivo is not fully understood. It is possible that more than one modi®cation or interaction with other cellular factors is needed to fully activate the p53 DNA-binding activity in vivo (Dee et al., 1995; . p53 stability and activity are dramatically elevated following DNA damage (Maltzman and Czyzyk, 1984; Kastan et al., 1991; Kuerbitz et al., 1992; Fritsche et al., 1993; Hall et al., 1993; Lu and Lane, 1993; Zhan et al., 1993; Nelson and Kastan, 1994) . However, the accumulation of p53 is not necessarily a prerequirement for the transcriptional activation of p53 Lu et al., 1996; HaapajaÈ rvi et al., 1997) . We have shown in mouse ®broblasts that the accumulation of p53 after U.V.C. treatment occurs only in cells at the G 1 /S-border or DNA-replicating cells in S-phase, whereas transcriptional activation of p53 target genes was found in all cell cycle phases (HaapajaÈ rvi et al., 1995 (HaapajaÈ rvi et al., , 1997 . Here we have further investigated the mechanisms that lead to accumulation and activation of p53 after U.V.C. We show the dependence of both p53 activation and accumulation on de novo protein synthesis and that the p53-activating signal induced by U.V.C remains continuous in the cells and can be sensed by the p53 activating machinery at least up to 6 h. The activated p53 is reactive to antibody PAb 421 as indicated by electrophoretic gel mobility shift assays suggesting that the C-terminal PKC phosphorylation site of p53 protein is not modi®ed in response to U.V.C. We have further tested the eects of various chemical kinase inhibitors on cellular p53 response and show that only staurosporine, but not speci®c PKC inhibitors are capable of interfering with the activation and accumulation of p53, further suggesting that PKC does not mediate the U.V.C. response in mouse ®broblasts.
Results
U.V.C. induces latent p53 DNA-binding activity but not accumulation of p53 in G 0 and G 1 -phases of the cell cycle
We have previously shown that U.V.C.-radiation of mouse NIH3T3 ®broblasts synchronized to G 1 -phase induces a transient 10 ± 12 h arrest of the cells (HaapajaÈ rvi et al., 1995) . Though U.V. increases the cellular levels of p53, the G 1 arrest is not accompanied by accumulation of p53 protein levels, which occurs only when cells have re-entered the cycle and proceed into S-phase. However, mRNAs for p53 transcriptional targets p21
CIP-1/WAF-1 and GADD45 are induced in G 0 /G 1 , G 1 /S and S-phases, similarly to p53-mediated transactivation, as measured by using p53-reporter constructs with speci®c p53-binding sequences stably expressed in the cells (HaapajaÈ rvi et al., 1997) . To further investigate the U.V.C.-induced transcriptional activation of p53 we U.V.C.-radiated (50 J/m 2 ) NIH3T3 cells synchronized to G 0 and mid G 1 -phases as described in Materials and methods. Nuclear extracts were prepared 6 h after the insult and gel mobility shift assays were performed using the consensus p53-binding site in the p21 CIP-1/WAF-1 gene promoter as a probe . In agreement with our previous results, U.V.C. induced the latent DNA-binding activity of p53 in both G 0 and G 1 cells, but not its accumulation (Figure 1a , lanes 3 and 5 and Figure 1b , lanes 2 and 4). Similar results on activation of p53 DNA-binding activity were obtained by using the consensus p53-binding site in the GADD45 gene promoter as a probe (data not shown), while the binding of p53 to its mutated p21 CIP-1/WAF-1 binding site was not aected by U.V.C. (Figure 1a, lane 15) .
To study the eects of U.V.C.-radiation on cells at the G 1 /S-border and in S-phase, cells were synchronized to G 1 /S-border by serum-starvation followed by replating of the cells in the presence of serum and hydroxyurea (HU). As previously shown, 480% of the cells released from HU-block progressed into S within 2 h (HaapajaÈ rvi et al., 1997). Subsequently, cells were radiated with U.V.C. at the G 1 /S-border or in early S (2 h after release from HU-block) and followed for 6 h. Time-dependence of the U.V.C.-induced p53 DNAbinding activity
As determined by gel mobility shift assays using nuclear extracts of U.V.C.-treated cells at the G 1 /Sborder, the p53 DNA-binding activity was induced by U.V.C. in 1 h and reached its maximum by 6 h ( Figure  2 , lanes 3 and 7, respectively). Longer incubation times after U.V.C. treatment did not result in further increase in the p53 DNA binding activity (data not shown). Similar time-dependence was observed also in G 0 , G 1 and S-phase cells (data not shown). The observed kinetics were slower than that elicited by gradiation which takes place within 30 min and peaks in 1 h ). To further demonstrate that the induced complex is speci®c for p53, nuclear extracts were incubated in the presence of p53 antibodies PAb 122 and 421. Both antibodies eciently supershifted the p53-DNA complexes ( U.V.-generated p53-DNA complexes and recognition by dierent p53 antibodies
To elucidate the activation of p53 by U.V.C. in dierent phases of the cell cycle, nuclear extracts prepared from cells U.V.C.-radiated at either G 1 and G 1 /S were incubated with increasing concentrations of p53 monoclonal antibody PAb 421. PAb 421 has been demonstrated to activate in vitro produced p53 by binding to its C-terminal epitope, thus generating a conformationally active form with an exposed transactivation domain (Hupp et al., 1992; Hupp and Lane, 1994a) . Titration of the U.V.C.-induced complex by PAb 421 antibodies (1 ± 500 ng) resulted in a gradual shift of the complex to slower migrating forms ( Figure  3a and b, lanes 4 ± 8). Low amounts of antibody (1 ± 10 ng, lanes 4 ± 6) resulted in the appearance of a faster migrating form which was fully supershifted with higher doses of the antibody (100 ± 500 ng, lanes 7 ± 8). The presence of two dierently migrating p53-DNA-antibody complexes is most likely the result of dierent stochiometric compositions of the complexes, e.g. 1 and 2 antibody molecules per p53 tetramer, respectively, for the faster and slower migrating supershifted forms. This is supported by the apparent 150 and 300 kd size dierences of the faster and slower migrating forms, respectively, from the p53-DNAcomplex. A small amount of PAb 421-activatable p53 protein was detected in the unirradiated control cells (Figure 3a and b, lane 3). The PAb 421 titration pattern was similar in extracts from G 1 and G 1 /S cells ( Figure 3a and b), suggesting that the amount of activatable p53 protein is similar in both cell cycle phases, and that all of it is PAb 421-reactive. This
UV HU 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 ) and incubated for 6 h in the presence (+) or absence (7) of HU as indicated, and nuclear extracts and cellular lysates were prepared for DNA-binding assays or immunoblotting, respectively. (a) gel mobility shift assays of G 0 , G 1 , G 1 /S and S-phase synchronized ®broblasts using p53-binding site in p21
CIP-1/WAF-1 promoter oligonucleotide (lanes 1 ± 13) or a mutated p53-binding site (lanes 14 and 15) as a probe. ) and nuclear extracts were prepared at indicated times. Gel mobility shift assays were performed in the absence (lanes 1 ± 7) or presence (lanes 8 ± 9) of indicated monoclonal antibodies (500 ng each) or excess cold probe (lanes 10 ± 11). Black arrow, p53-DNA complex; bar, supershifted p53-DNA complex again dierentiates the transactivation events from the observed absence of protein accumulation in G 0 /G 1 cells. Further, monoclonal antibodies PAb 122 and 246 recognized p53 in the p53-DNA complexes, whereas PAb 240 did not, indicating that p53 is in the wildtype conformation (Figure 3a and b, lanes 9 ± 11).
Protein synthesis is required for both p53 accumulation and its DNA-binding activity by U.V.C.
In order to study the requirements of p53 accumulation and activation by U.V.C., cells were exposed to various chemical treatments to elucidate how they aect the respective processes. Cycloheximide (CHX) has previously been indicated to inhibit the accumulation of U.V.C.-induced p53 (Lu and Lane, 1993) . U.V.C.-treated G 1 /S synchronized cells were incubated in the presence of CHX for various lengths of time, either 15 min prior the U.V.C. or for 1 ± 6 h after the insult followed by subsequent removal of the drug and further incubation of the cells in fresh medium up to a total time of 6 h after the insult. As shown by Western blotting analysis, p53 accumulation was prevented only if CHX was present on the cells for the whole 6 h incubation time (Figure 4a , lane 8), but not if the cells were released from the CHX block 4 h after U.V.C. and were further incubated for 2 h (Figure 4a , lane 7). CHX prevented U.V.C.-induced p53 DNA-binding activity at similar kinetics as protein accumulation. Preincubation of the cells for 15 min in the presence of CHX prior U.V.C. or incubation for 1 ± 4 h after U.V.C., followed by washing o the drug, allowed full restoration of the DNA-binding activity by 6 h (Figure 4b, lanes 3 ± 7) . The events for the last hour were further screened in a similar manner by releasing the cells from CHX 5, 5.5, and 6 h after U.V.C. and preparing extracts 6 h after the U.V.C.-insult (Figure 4c , lanes 4 ± 6), demonstrating that the cells required a 2 h CHX-free period for activation of p53. As shown by immunoblotting analysis the induction of p21 fully correlated to the presence of active p53 (Figure 4a bottom panel, lanes 3 ± 7). As p53 accumulation and activation was found to be independent of inhibition of DNA replication in the G 1 /S-boundary cells, the eect of CHX on the respective processes was further tested in the presence of HU. Incubation of G 1 /S U.V.C.-treated cells in the presence of HU and CHX was found to abolish both p53 accumulation (Figure 4d Based mostly on in vitro experiments it has been proposed that phosphorylation events mediate the p53 response to DNA damage. The physiological importance of these events is, however, not clear. One of the kinases that phosphorylate p53 in vitro is PKC (Baudier et al., 1992; Delphin and Baudier, 1994; Takenaka et al., 1995) . Therefore we wanted to test the eect of modulation of PKC activity on the U.V.C.-induced accumulation and activation of p53 in our in vivo model system. As can be seen in Figure 5a , lane 4, the accumulation of p53 in G 1 /S cells was inhibited by staurosporine, a known inhibitor of PKC but also of a wide range of other protein kinases. In contrast, speci®c PKC inhibitors chelerythrine and bisindolylmaleimide IV had no eect on the U.V.C. (Figure 5b ). Staurosporine has previously been shown to arrest normal cells in G 1 at low doses (1 ± 4 nM) (Bruno et al., 1992; Crissman et al., 1991) . To resolve whether the observed eects of staurosporine on p53 are due to its cell cycle regulation, DNA replication of staurosporine-treated cells was estimated by 5-bromo 2-deoxyuridine incorporation followed by immunohistochemistry at dierent phases of the cell cycle. Staurosporinetreated G 1 cells arrested eciently, and did not proceed into S, whereas DNA replication of cells treated in G 1 / S and S-phases was unaected (not shown). This excludes that the observed eect of staurosporine on p53 accumulation is replication-dependent. Further, other kinase inhibitors were tested in a similar manner, including tyrosine kinase inhibitors genistein and lavendustin A, serine/threonine kinase inhibitor olomoucin and casein kinase I and II inhibitors A3 and 5,6-dichloro-1-b-D-ribofuranosylbenzimidazole. None The kinetics of staurosporine-mediated inhibition of p53 accumulation and DNA-binding activity were tested in G 1 /S-phase U.V.C.-treated cells. Cells were incubated with staurosporine 15 min prior or 0.5 ± 4 h after the U.V.C.-insult followed by washing o the drug and further incubation of the cells up to 6 h. Even a short 2 h exposure of the cells to staurosporine immediately after the insult did not allow full restoration of either p53 DNA-binding or its accumulation at later stages (Figure 7a and c, lane 6). Quantitations of the p53 DNA-binding complex by PhosphorImage analyser indicated that staurosporine decreased the amount of the induced complex by up to 60% if present on the cells for the ®rst 1 ± 2 h after the insult (Figure 7b ). This correlated with a decrease in the amount of induced p21 WAF-1, CIP-1 protein (Figure 7c , lanes 5 and 6). The results suggest that staurosporine, in contrast to CHX, blocks an relatively early event in the U.V.-signalling cascade which cannot be fully reconstituted at a later time.
To further elucidate PKC-pathway as a mediator of p53 activation, cells were treated with increasing concentrations of phorbol 12-myristate 13-acetate (PMA) (10 ± 100 nM), a potent activator of PKC, for various lengths of time (20 min ± 6 h). An example of these studies is shown in Figures 5 and 8 , indicating that PMA did not induce p53 accumulation and had no eect on basal DNA-binding activity of p53 nor on the activation of p53 by U.V.C. (Figure 5a , lane 3, 
Discussion
We have studied here the U.V.-activated pathways that lead to accumulation and activation of p53 and demonstrate cell cycle-dependent dierences in their respective responses. We have previously shown that U.V.C.-mediated accumulation of p53 takes place in G 1 /S and replicating S-phase cells, but not in G 0 /G 1 (HaapajaÈ rvi et al., 1995 (HaapajaÈ rvi et al., , 1997 , whereas activation of p53 target genes, p21
WAF-1,CIP-1 and GADD45 is cell cycle-independent. We con®rm the above ®ndings demonstrating that U.V.C. induces p53 DNA-binding activity as measured by p53 oligonucleotide-binding sequences from both p21 and GADD45 promoters and further demonstrate that the activation takes place cell cycle-independently and in replication-de®cient cells. The results support the notion that p53 accumulation is not a prerequisite for its increased DNA-binding activity and thus activation (Lu and Lane, 1993; Bond et al., 1996; Lu et al., 1996) .
In contrast to other DNA-damaging factors, U.V.C. increased p53 DNA-binding activity at rather slow kinetics starting 1 h after the insult and steadily increasing thereafter. The kinetics of activation were the same in dierent phases of the cell cycle again demonstrating that the amount of accumulated p53 is not a major determinant required for p53 activation. Furthermore, as shown by antibody titration experiments using p53 C-terminus speci®c antibody PAb 421 (mouse epitope 363 ± 372; Lane et al., 1996) the amount of p53 with speci®c DNA-binding activity was the same in both cases. Interestingly, low amounts of antibody (1 ± 10 ng) generated a p53-DNA complex of intermediary size, whereas high amounts (100 ± 500 ng) generated a slow migrating high molecular weight protein-DNA complex. This suggests dierent stochiometric amounts of antibodies bound to p53-DNA complexes. In contrast, only the higher molecular weight p53-DNA complex has been detected previously in studies using either recombinant p53 or insect cell-derived p53 (Hupp et al., 1992; . The discrepancy suggests dierent conformational forms for mammalian U.V.-activated p53 recognized by PAb 421. p53 is an allosterically regulated, oligomeric protein. PAb 421 has also the ability to conformationally activate latent p53 through carboxyterminal interaction (Hupp et al., 1992 . However, the U.V.-activated p53-DNA complex is fully recognized and is completely supershifted by high amounts of PAb 421, as well as PAb 122, recognizing the same epitope. This contrasts the ®ndings of in U.V.-treated serum-starved insect cells, where a pool of activated PAb421-unreactive p53 was found. The observed PAb 421-reactivity of p53 is suggestive that possible U.V.-mediated modi®cations occur in another manner than C-terminal regulation. Similarly, the complex is recognized by PAb 246 recognizing wildtype p53, but not by conformation speci®c antibody PAb 240 recognizing mutant p53.
Previous studies have shown the dependence of damage-associated p53 on cellular protein synthesis which has been linked to increased p53 post-translational stabilization (Maltzman and Czyzyk, 1984; Kastan et al., 1991; Fritsche et al., 1993; Tishler et . Our results that show the inhibitory eect of CHX on U.V.-mediated accumulation concur with those above, but raise some further points on the activation of p53. First, the inhibition of p53 activation by CHX took place in all phases of the cell cycle including the G 0 and G 1 -phases, at which time there is no or little accumulated p53 present in the cells. This is suggestive of the requirement of synthesis of protein(s), possibly other than p53, for its activation in G 0 /G 1 . Secondly, CHX was inhibitory to p53 only if it was present almost continuously on the cells. The addition of CHX at the time of the insult followed by a release 2 h before the end of the incubation was sucient for full p53 accumulation and activation. Taking into account the kinetics of p53 activation in Figure 2 , which show that by 2 h only a fraction of p53 is activated, and that 6 h is required for its full activation, an interesting discrepancy in the kinetics is observed. This suggests that the signal(s) initiated by U.V.C. that leads to p53 activation is not a transient one but is maintained in the cells for long periods of time. As the activation after CHX release is rapid, but not imminent, and protein synthesis is required, it seems that activation of an existing pool of p53 is not sucient, though its stabilization may be bypassed e.g. in G 0 /G 1 cells. It is also plausible that alternative modi®cations of p53 predisposing to activation may take place during the protein synthesis block. Furthermore, as shown in Figure 4d and e, CHX blocked also the replication-independent accumulation and activation of p53 in G 1 /S-phase cells. p53 transcriptional activation takes place also independently of protein synthesis e.g. in quiescent ®broblasts where serum stimulation in the presence of CHX leads to an increase in p21 mRNA in a p53-dependent manner (Macleod et al., 1995) , and on the other hand, p53 is subject to activation through direct C-terminal modi®cation . This further underscores multiple pathways Staurosporine, though potent inhibitor of PKC kinase, is an inhibitor with similar IC 50 of PKA, PKG, cyclin-dependent kinases (CDK)-1 and -2 and Src tyrosine kinase (Gadbois et al., 1992; Meijer, 1996) . Staurosporine arrests cycle of normal cells in G 1 and G 2 presumably by inhibition of CDK1 and CDK2 which is potentiated by an increase of p21 and p27 CDK inhibitors (Schnier et al., 1996) . Staurosporine was found to inhibit p53 activation in all phases of the cell cycle, and inhibit the protein accumulation in G 1 /S and S. Staurosporine-mediated inhibition of p53 accumulation and activation diered from that observed by CHX in two manner. Firstly, it was capable of only halfmaximal inhibition of DNA-binding activity, and secondly, the kinetics of inhibition of both activation and accumulation suggested that it blocks an early event in the damage response pathway, which is not fully reconstituted at later stages. Though considerable amount of evidence indicates that PKC is an activator of p53 via its phosphorylation of the carboxyterminal recognition site (Baudier et al., 1992; Delphin and Baudier, 1994; Hupp and Lane, 1994a; Takenaka et al., 1995) , it is unlikely that PKC would be the mediator of the U.V.C.-activation of p53. This is based on the following observations. Speci®c PKC inhibitors chelerythrine and bisindolylmaleimide I and IV were unable to aect either p53 activation or its accumulation. Formally, however, it remains possible that an isoform of PKC recognized by staurosporine, but not by chelerythrine and bisindolylmaleimide I or IV, is responsible for the p53 U.V.-activation pathway. Similarly, treatment of the cells with PMA, known to activate the PKC pathway, either in U.V.-treated or control cells was unable to modulate the p53 DNAbinding activity or its accumulation. Furthermore, the PKC phosphorylation of p53 in vitro is reported to inhibit the PAb 421 binding (Delphin and Baudier, 1994; Hupp and Lane, 1994a; Takenaka et al., 1995) , and speci®c DNA-binding of p53 concurs with the phosphorylation of the PKC site and leads to lack of PAb 421 reactivity. However, in all of our assays, including the PMA-treated cells, the PAb 421 reactivity is retained, further suggesting that the PAb 421 epitope is not masked by PKC phosphorylation. In addition, in murine cells the PAb 421 epitope containing PKC phosphorylation sites was not aected by PMAtreatment supporting the view that PKC does not aect p53 phosphorylation in vivo (Milne et al., 1996) . We have also tested a number of protein kinase inhibitors known to share substrates with PKC and their combinations with staurosporine in order to resolve which is the U.V.-activated p53 kinase and whether phosphorylations by multiple kinases are required. Of these, tyrosine kinase inhibitors that also inhibit the U.V.-activation pathway (Derijard et al., 1994) and CDK1 and -2 inhibitor olomoucine were without eect on p53 activation. Similarly, inhibitors of other kinases, such as casein kinase II inhibitors and Ca 2+ /calmodulin inhibitor, did not aect the p53 U.V.-responses.
Taking together, the results demonstrate that p53 DNA-binding activity is stimulated by U.V.C. in the absence of protein accumulation. p53 activation is cell cycle and DNA replication-independent, whereas accumulation is observed only in G 1 /S-phase and in replicating S-phase cells. CHX completely abolished p53 activation in G 1 cells in which U.V. did not induce the accumulation of p53, substantiating the dissociation of activation and accumulation. In concordance, staurosporine inhibited p53 accumulation whereas it caused only half-maximal inhibition of DNA-binding activity. The results indicate that U.V.C.-mediated activation of p53 depends on two, perhaps overlapping pathways requiring protein synthesis and protein phosphorylation.
Materials and methods

Reagents
Hydroxyurea and cycloheximide were from Sigma. Staurosporine, bisindolylmaleimide I and IV, chelerythrine, lavendustin A, olomoucin, genistein and phorbol 12-myristate 13-acetate (PMA) were from LC Laboratories. A3, 5,6-dichloro-1-b-D-ribofuranosylbenzimidazole and K252a were from Calbiochem. p53 monoclonal antibodies PAb 122, 240 and 246 were from Pharmingen and PAb 421 from Oncogene Sciences. p21 polyclonal antibody 13436E was from Pharmingen.
Cell culture, synchronization and U.V.-treatment NIH3T3 mouse ®broblasts (ATCC CRL 1658) were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% newborn calf serum (NBCS; Gibco-BRL). Synchronization and U.V.-treatment of cells was carried out essentially as described previously (HaapajaÈ rvi et al., 1995 (HaapajaÈ rvi et al., , 1997 . Cells were synchronized to G 0 /G 1 by incubation of con¯uent cultures in the presence of 0.2% NBCS for 8 h and released by replating the cells at 1 : 3 ratio in culture medium containing 10% NBCS. Flow cytometry analyses and 5-BrdU immunostainings showed that the cells were in G 1 with less than 5% of cells replicating DNA 6 h after release, at which time G 1 -synchronized cells were radiated. Cells were synchronized to G 1 /S by initial serum-starvation followed by replating of the cells with fresh medium in the presence of 0.25 mM hydroxyurea (HU) (Sigma) and incubation for 16 h, after which plates were washed, medium was removed and cells were exposed to U.V.C. (254 nm) at a dose of 50 J/m 2 with Stratalinker 1800 (Stratagene). Fresh medium was added and cells were incubated for the indicated periods of time. The S-phase synchronized cells were incubated for additional 2 h after removal of HU block, exposed to U.V.C. and incubated for the indicated periods of time.
Gel mobility shift assay
Nuclear extracts were prepared as previously described (Andrews and Faller, 1991) . Oligonucleotides representing the consensus p53 binding site either in the p21 CIP-1/WAF-1 gene promoter , 5'-AATTCTCGAG-GAACATGTCCCAACATGTTGCTCGAG-3' or mutated p53 binding site, 5'-AATTCTCGAGGAAAATTTCC-CAAAATTTTG-CTCGAG-3' (mutated bases underlined) were synthesized, annealed into double-stranded form and labeled with 32 P using T4 polynucleotide kinase (New England Biolabs). Binding reactions contained 15 mg of nuclear extract, 10 ml of 26binding buer (40 mM HEPES ± KOH pH 7.9, 50 mM KCl, 0.2 mM EDTA, 20% glycerol, 4 mM MgCl, 1 mM DTT, 0.05% NP-40), 4 mM spermidine (Sigma), 100 ng poly dI-dC (Pharmacia) and monoclonal antibody (where indicated) in a ®nal volume of 20 ml. Binding reactions were incubated at room temperature for 10 min, 0.2 ng of oligonucleotide probe was added and incubation was continued for additional 20 min at room temperature. Reaction products were separated on a 4% nondenaturing polyacrylamide gel with 5% glycerol in 0.256TBE buer at 48C. The gel was dried and analysed by autoradiography and, as indicated, quantitated by Fuji BAS-1500 image analyser and MacBAS 2.1 program.
Immunoblotting analysis
Immunoblotting assays were carried out as described earlier (HaapajaÈ rvi et al., 1995) . Brie¯y, cells were lysed with 25 mM Tris-HCl buer, pH 8.0, containing 120 mM NaCl, 0.5% NP-40, 4 mM NaF, 100 mM Na 3 VO 4 , 100 KIU/ ml aprotinin, 1 mM phenylmethyl sulfonyl¯uoride and 10 mg/ml leupeptin. Lysates (150 mg) were analysed by 12.5% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS ± PAGE) followed by transfer of proteins to membrane, probing with monoclonal antibody PAb 240 against p53 (Pharmingen) and polyclonal antibody 13436E against p21 (Pharmingen) and detection with enhanced chemiluminescence (ECL, Amersham).
